Bệnh gan nhiễm mỡ liên quan chuyển hóa: tỷ lệ và mức độ xơ hóa gan đánh giá bằng Fibroscan

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Xuân Phát Lưu, Minh Đức Nguyễn, Nguyễn Diễm Hồng Tống

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y Dược học Phạm Ngọc Thạch, 2024

Mô tả vật lý: tr.159

Bộ sưu tập: Metadata

ID: 442077

Thêm vào giỏ Liên kết toàn văn

Khái niệm bệnh gan nhiễm mỡ liên quan chuyển hóa (MAFLD) là một định nghĩa thay thế cho bệnh gan nhiễm mỡ không do rượu (NAFLD). Định nghĩa mới cho phép xác định nhóm bệnh nhân có nhiều yếu tố nguy cơ xơ hóa gan hơn. Ngoài ra, MAFLD còn có thể chẩn đoán chung với các bệnh lý gan khác tạo điều kiện cho các nghiên cứu tìm hiểu về đặc điểm của các nhóm bệnh nhân mới này. Mục tiêu: Xác định tỷ lệ và mức độ xơ hóa gan, mức độ nhiễm mỡ gan bằng FibroScan ở bệnh nhân MAFLD đơn thuần và MAFLD có đồng mắc bệnh lý gan khác. Phương pháp: Nghiên cứu cắt ngang bệnh nhân có tình trạng gan nhiễm mỡ tại phòng khám Đại Phước. Gan nhiễm mỡ được xác định khi chỉ số CAP >
233 dB/m (tương đương nhiễm mỡ ≥ 5% gan) đo bằng FibroScan. Mức độ xơ hóa gan được đánh giá bằng chỉ số độ đàn hồi đo bằng FibroScan. Kết quả: Chúng tôi thu được 204 bệnh nhân gan nhiễm mỡ thỏa các tiêu chuẩn chọn mẫu. Tỷ lệ bệnh nhân MAFLD là 89,7%, trong đó bệnh nhân MAFLD đơn thuần chiếm 62,8% và MAFLD có bệnh gan đồng mắc chiếm 27,0%. Độ đàn hồi trung bình của nhóm MAFLD đơn thuần và nhóm MAFLD có đồng mắc là 5,1 và 6,0 kPa. Tỷ lệ xơ hóa gan đáng kể (≥ F2) nhóm MAFLD có đồng mắc cao hơn nhóm MAFLD đơn thuần (29,1% so với 10,2%, p <
0,001). Trong phân tích hậu định, sự khác biệt xơ hóa gan chủ yếu ở nhóm MAFLD có sử dụng rượu và nhóm đơn thuần (độ đàn hồi 6,8 so với 5,1 kPa, p <
0,001). Kết luận: Nghiên cứu chúng tôi cho thấy tỷ lệ MAFLD ở bệnh nhân gan nhiễm mỡ Việt Nam chiếm tỷ lệ cao và MAFLD đồng mắc với các bệnh lý gan khác có tỷ lệ xơ hóa gan đáng kể cao hơn MAFLD đơn thuần.Abstract The concept of metabolic-associated fatty liver disease (MAFLD) is a replacement definition for non-alcoholic fatty liver disease (NAFLD). This new definition allows for the identification of patient groups with a higher risk of liver fibrosis. Additionally, MAFLD can coexist with other liver diseases, facilitating research into the characteristics of these new patient groups. Objective: To determine the prevalence and degree of liver fibrosis, as well as the degree of hepatic steatosis using FibroScan in patients with MAFLD - only and those with MAFLD coexisting with other liver diseases. Methods: A cross - sectional study was conducted on patients with fatty liver at the Dai Phuoc Clinic. Fatty liver was identified when the Controlled Attenuation Parameter (CAP) was >
233 dB/m (equivalent to ≥ 5% liver fat) measured by FibroScan. The degree of liver fibrosis was assessed using the liver stiffness measurement obtained by FibroScan. Results: We included 204 fatty liver patients meeting the sample selection criteria. The prevalence of MAFLD was 89,7%, MAFLD - only patients accounting for 62,8% and those with co - existing liver diseases accounting for 27,0%. The average liver stiffness of the MAFLD-only group and the coexisting group was 5,1 and 6,0 kPa, respectively. The significant fibrosis rate (≥ F2) in the coexisting MAFLD group was higher than in the MAFLD - only group (29,1% vs 10,2%, p <
0,001). In the post - hoc analysis, the difference in liver fibrosis was primarily in the group with MAFLD and alcohol use compared to the MAFLD-only group (liver stiffness 6,8 vs. 5,1 kPa, p <
0,001). Conclusion: Our study reveals a high prevalence of MAFLD in Vietnamese fatty liver patients, with coexisting MAFLD and other liver diseases showing a significantly higher rate of liver fibrosis than MAFLD - only. DOI: 10.59715/pntjmp.3.1.18

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR